Loading
Life sciences · Journal article
Journal of Visualized Experiments · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic/bariatric surgery is an effective intervention for people with obesity and type 2 diabetes mellitus (T2DM), with benefits extending beyond weight loss. This focused review examines long-term glycemic outcomes after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), one-anastomosis gastric bypass (OAGB), and adjustable gastric banding (AGB). Because reported remission depends on glycated hemoglobin thresholds, medication rules, and follow-up duration, we distinguish durable glycemic improvement from consensus-defined remission. We compare procedure-specific evidence and discuss adiposity, insulin sensitivity, pancreatic β-cell function, incretin hormones, bile acid signaling, and gut microbiota within an integrated intestine-liver-pancreas axis. RYGB and OAGB often show strong metabolic effects, but no operation is universally superior; procedure selection must balance efficacy against reflux, nutritional deficiencies, dumping, postbariatric hypoglycemia, and revisional needs. Current recommendations support considering surgery for eligible adults with T2DM and obesity. Lifelong multidisciplinary follow-up is required for glycemia, micronutrients, bone health, gastrointestinal symptoms, hypoglycemia, and weight recurrence. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 therapies may serve as alternatives, bridges, or postoperative adjuncts, although post-surgical evidence remains limited. Harmonized endpoints and prospective comparative studies are needed to improve individualized care.